Laboratory Co News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Laboratory co. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Laboratory Co Today - Breaking & Trending Today
Redwood Investment Management LLC bought a new position in shares of Laboratory Co. of America Holdings (NYSE:LH – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 20,458 shares of the medical research company’s stock, valued at approximately $4,650,000. Other institutional investors […] ....
Fortrea (NASDAQ:FTRE – Get Free Report) and Laboratory Co. of America (NYSE:LH – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Insider & Institutional Ownership 95.9% of Laboratory […] ....
Morningstar Investment Management LLC bought a new stake in Laboratory Co. of America Holdings (NYSE:LH – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,146 shares of the medical research company’s stock, valued at approximately $260,000. […] ....
Peapack Gladstone Financial Corp boosted its stake in Laboratory Co. of America Holdings (NYSE:LH – Free Report) by 0.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 92,871 shares of the medical research company’s stock after buying an additional 445 […] ....
Laboratory Co. of America (NYSE:LH – Get Free Report) had its price target decreased by research analysts at JPMorgan Chase & Co. from $261.00 to $243.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price points to […] ....